Prevotella Merdae Strain for Checkpoint Inhibitor Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments, including chemical anticancer drugs and immunotherapies, face challenges such as drug resistance and variable efficacy due to cancer cell mutations, necessitating a novel approach to enhance immunity and increase anticancer effects.
Innovation Solution
A novel Prevotella merdae Immunoactis strain (accession number: KCTC 14922BP) is used to enhance immunity and increase the efficacy of immune checkpoint inhibitors by promoting T cell proliferation, increasing IFN-γ secretion, and modulating the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical anticancer drugs are used, then cancer cell proliferation is suppressed, but normal cells are also affected causing side effects and decreased immunity
Solution Approach 1:
The patent introduces probiotic bacteria (Lactobacillus casei, Bifidobacterium animalis, etc.) as intermediary agents that modulate the tumor microenvironment and enhance immune cell function. These probiotics act as mediators between the anticancer treatment and the host immune system, improving immune response while reducing the harmful effects of chemical drugs on normal cells.
Solution Approach 2:
The patent converts the harmful effects of chemical anticancer drugs into beneficial outcomes by using probiotic bacteria to counteract the drug-induced immune suppression and intestinal dysfunction. The probiotics transform the damaged tumor microenvironment into a more favorable state for immune-mediated cancer cell destruction.
2Object-affected harmful factors
If targeted anticancer drugs are used, then side effects are reduced, but cancer cells develop drug resistance due to rapid mutation
Solution Approach 1:
The patent employs a dynamic approach by using probiotic bacteria that can adaptively modulate the tumor microenvironment and immune response. The probiotics dynamically interact with cancer cells and immune cells, continuously adjusting the immune landscape to maintain anticancer efficacy despite cancer cell mutations and drug resistance development.
Solution Approach 2:
The patent changes the parameters of the tumor microenvironment through probiotic administration, altering pH, oxygen levels, and immune cell infiltration. These parameter changes create a hostile environment for cancer cells and enhance the effectiveness of targeted drugs, preventing resistance development.
3Reliability
If immune checkpoint inhibitors are used, then immune cell function is activated to suppress cancer cell proliferation, but the treatment does not exhibit the same effect in all patients
Solution Approach 1:
The patent introduces probiotic bacteria as intermediary agents that prepare and optimize the tumor microenvironment before and during immune checkpoint inhibitor treatment. The probiotics act as mediators that enhance the penetration and effectiveness of checkpoint inhibitors by modifying the immune landscape and reducing physical barriers in the tumor microenvironment.
Solution Approach 2:
The patent applies probiotic bacteria as a preliminary treatment to condition the tumor microenvironment and prime the immune system before administering immune checkpoint inhibitors. This preliminary action enhances the responsiveness of immune cells to checkpoint blockade, increasing the likelihood of treatment success across different patient populations.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention relates to a novel Prevotella merdae Immunoactis strain, use thereof, and the like. The inventors of the present invention have confirmed that the novel Prevotella merdae Immunoactis strain (accession number: KCTC 14922BP) increases the proliferation of T cells, increases IFN-γ secretion from T cells, increases the expression or activity level of IFN-γ or Cxcl9, reduces the expression or activity level of Ccl22, and enhances the anticancer efficacy of immune checkpoint inhibitors. Therefore, the novel Prevotella merdae Immunoactis strain or a culture broth thereof, according to the present invention, is expected to be effectively used for enhancing immunity and increasing the anticancer effect of immune checkpoint inhibitors.